Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment.
The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.
Niaura
Raymond
R
Centers for Behavioral and Preventive Medicine, The Miriam Hospital and Brown Medical School, Providence, Rhode Island 02903, USA. raymond_niaura@brown.edu
Spring
Bonnie
B
Borrelli
Belinda
B
Hedeker
Donald
D
Goldstein
Michael G
MG
Keuthen
Nancy
N
DePue
Judy
J
Kristeller
Jean
J
Ockene
Judy
J
Prochazka
Allan
A
Chiles
John A
JA
Abrams
David B
DB
D000328:Adult; D001521:Behavior Therapy / Q000379:methods*; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016540:Smoking Cessation; D000074606:Smoking Prevention
D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors